Diabetes Medication For Patients With Alzheimer's Disease
(diabetes have a tendency to develop pigmented spots on the brain)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
The team, led by neuropathologist Toru Iwaki, found that people whose blood glucose levels tend to remain high after meals also tend to develop the lesions, which typically are found in the elderly. The finding suggests people may be able to prevent themselves from developing Alzheimer's disease by working to prevent diabetes through exercise and careful eating habits (http://onlineathens.com/stories/091410/liv_707406950.shtml).
A pilot study suggests the diabetes medication pioglitazone is generally well tolerated and may warrant further study as a treatment for patients with Alzheimer's disease, according to a report posted online today that will appear in the January 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.
"Alzheimer's disease is an immense and growing public health problem," the authors write as background information in the article. "Although prescription drug therapy for the symptoms of Alzheimer's disease has been available since 1993, these agents do not fundamentally alter the pathological expression of the disease or its progressive course. The failure of several recent treatment trials directed at the beta-amyloid peptide, a key pathological correlate of Alzheimer's disease, suggests a need to explore alternative approaches to Alzheimer's disease treatment that are not focused on beta-amyloid metabolism."
Another potential therapeutic target for the treatment of Alzheimer's disease is the nuclear receptor peroxisome proliferator–activated receptor gamma, PPAR-gamma, which acts to regulate glucose and lipid metabolism. A class of drugs known as thiazolidinediones, originally developed to reduce insulin resistance in patients with type 2 diabetes, are potent agonists (trigger a response) of PPAR-gamma. To evaluate the safety of one of these medications, pioglitazone, in patients without diabetes but with Alzheimer's disease, David S. Geldmacher, M.D., of the University of Virginia Health System, Charlottesville, and colleagues conducted an 18-month, double-blind, placebo-controlled randomized controlled trial. Twenty-nine patients without diabetes but with probable Alzheimer's disease were randomly assigned to receive either pioglitazone (titrated to 45 milligrams daily) or matching placebo, along with 200 international units of vitamin E. Read more: redorbit.com onlineathens.com
Olive extract’s bone benefits
The potential bone health benefits of the olive polyphenol, oleuropein, are related to its ability to stimulate cells responsible for bone formation, says a new study that explains the mode of action of the compound. Read more: nutraingredients.com
No comments:
Post a Comment